Blog

Indian Pharma Exports Reach USD 29 Billion in FY26: Generics and Global Demand Drive Growth

  • Post category:News

Indian Pharma Exports Reach USD 29 Billion in FY26: Generics and Global Demand Drive Growth

India’s pharmaceutical export sector continues its strong upward trajectory, clocking approximately USD 29 billion in exports by the end of February in FY2025-26, according to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil). This represents sustained growth driven by the global demand for Indian generic medicines, biosimilars, and active pharmaceutical ingredients (APIs).

India on Track for USD 30 Billion Export Milestone

India’s pharmaceutical exports reached USD 30.47 billion in FY 2024-25, registering a year-on-year growth of 9.4 per cent, as reported by Pharmexcil in its 21st Annual General Meeting held in December 2025. The momentum has carried into FY2025-26, with exports reaching approximately USD 29 billion by the end of February 2026, according to K. Raja Bhanu, Director General of PHARMEXCIL, as reported by Business Standard (April 2026).

The sector, currently valued at approximately USD 60 billion, is projected to grow to USD 130 billion by 2030, driven by increasing global demand for affordable generic medicines and India’s reputation as the “Pharmacy of the World.”

Generic Medicines: The Backbone of Export Growth

Indian generic medicines continue to be the primary driver of export growth, accounting for over 20% of the global generic medicine supply by volume. The United States remains the largest destination market, followed by the European Union, Africa, and Southeast Asia. India supplies approximately:

  • 40% of generic medicines to the United States
  • 25% of all medicines consumed in the United Kingdom
  • Significant shares of antiretroviral (ARV) drugs for global HIV/AIDS treatment programs
  • A growing share of biosimilars and complex generics to regulated markets

Market Diversification and Quality Focus in 2026

Pharmexcil has identified quality enhancement and market diversification as key priorities for 2026, as reported by ETPharma.com. The council is actively working with the Ministry of Commerce and Industry to:

  • Strengthen WHO-GMP compliance across small and medium-sized pharma enterprises (MSMEs)
  • Expand into emerging markets in Latin America, Central Asia, and Africa
  • Promote investment in R&D for biosimilars and novel drug delivery systems
  • Address supply chain resilience and minimize dependence on single-source API imports

The Ministry of Commerce and the Department of Pharmaceuticals have held strategic consultations with Pharmexcil to align policy support, MSME participation, and regulatory frameworks to sustain India’s competitive edge in global pharma markets.

Challenges: Geopolitical Risks and Freight Disruptions

Despite the strong growth trajectory, the sector faces headwinds. Pharmexcil has warned that rising geopolitical tensions in West Asia and associated maritime disruptions could threaten up to USD 600 million in Indian pharmaceutical exports, as reported by Pharmaceutical Commerce (March 2026).

In a separate development, Pharmexcil has urged the government to provide freight subsidies and logistical support, warning that global freight market disruptions could lead to losses of up to ₹5,000 crore (approximately USD 600 million) for Indian pharma exports, as reported by The Hindu BusinessLine (March 2026).

Key challenges include:

  • Increased shipping container costs due to Red Sea route disruptions
  • Delays in raw material imports, affecting API production schedules
  • Price competition from Chinese manufacturers in bulk drugs and intermediates
  • Stricter regulatory scrutiny in regulated markets (USFDA, EMA) requiring enhanced quality compliance

Government Support and the PLI Scheme

The Indian government’s Production Linked Incentive (PLI) scheme for pharmaceuticals, launched with a financial outlay of approximately ₹15,000 crore (USD 1.8 billion), has been instrumental in boosting domestic manufacturing of critical APIs, key starting materials (KSMs), and drug intermediates. The scheme aims to reduce import dependence on China for critical drug components while increasing India’s export competitiveness.

With the Indian pharmaceutical industry targeting USD 130 billion in sector valuation by 2030, the government’s continued focus on regulatory modernization, WTO-compliant IP frameworks, and trade facilitation will be pivotal in achieving this ambition.

How Buyers Can Access India’s Pharma Export Market

For international buyers seeking to source high-quality Indian generic medicines, working with verified distributors is essential to ensure product authenticity, regulatory compliance, and reliable supply chains. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA member directory.

For more information, contact IMSDA at contact@indiamedicine.org.

Tags: , ,